{
    "id": 1220,
    "fullName": "TSC1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TSC1 mutant indicates an unspecified mutation in the TSC1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 7248,
        "geneSymbol": "TSC1",
        "terms": [
            "TSC1",
            "LAM",
            "TSC"
        ]
    },
    "variant": "mutant",
    "createDate": "07/31/2014",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1247,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "A retrospective study of a Phase II trial correlated increased sensitivity to the mTOR inhibitor Afinitor (everolimus) with TSC1 mutations in bladder cancer patients (PMID: 22923433).",
            "molecularProfile": {
                "id": 1244,
                "profileName": "TSC1 mutant"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 431,
                    "pubMedId": 22923433,
                    "title": "Genome sequencing identifies a basis for everolimus sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22923433"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20726,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with Afinitor (everolimus) or Torisel (temsirolimus) resulted in more partial responses (odds ratio = 0.08, p=0.030) in patients with renal cell carcinoma harboring mTOR pathway mutations, including MTOR (n=8), TSC1 (n=1), and TSC2 (n=2), than those without mutations (n=76) (PMID: 31335987).",
            "molecularProfile": {
                "id": 1244,
                "profileName": "TSC1 mutant"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18013,
                    "pubMedId": 31335987,
                    "title": "PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31335987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16899,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (EXIST-1), Afinitor (everolimus) treatment resulted in a 50% or more tumor reduction in 35% (27/78) of adult and pediatric patients diagnosed with tuberous sclerosis complex and had subependymal giant cell astrocytoma, compared to 0% (0/39) in the placebo group, 85% (99/117) of the patients harbored mutations in TSC1 and/or TSC2 (PMID: 23158522; NCT00789828).",
            "molecularProfile": {
                "id": 1244,
                "profileName": "TSC1 mutant"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5077,
                "name": "subependymal giant cell astrocytoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15037,
                    "pubMedId": 23158522,
                    "title": "Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23158522"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16245,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 1244,
                "profileName": "TSC1 mutant"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20717,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with Afinitor (everolimus) or Torisel (temsirolimus) resulted in more partial responses (odds ratio = 0.08, p=0.030) in patients with renal cell carcinoma harboring mTOR pathway mutations, including MTOR (n=8), TSC1 (n=1), and TSC2 (n=2), than those without mutations (n=76) (PMID: 31335987).",
            "molecularProfile": {
                "id": 1244,
                "profileName": "TSC1 mutant"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 18013,
                    "pubMedId": 31335987,
                    "title": "PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31335987"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15184,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, TSC1, TSC2, or MTOR mutation status was not associated with progression-free survival in renal cell carcinoma patients treated with Afinitor (everolimus) (PMID: 30327302).",
            "molecularProfile": {
                "id": 1244,
                "profileName": "TSC1 mutant"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 12807,
                    "pubMedId": 30327302,
                    "title": "PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30327302"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17206,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, ABI-009 (Nab-Rapamycin) treatment of malignant perivascular epithelioid cell patients resulted in partial response in 20% (1/5) of patients with TSC1 mutations, 100% (9/9) of patients with TSC2 patients, and 9% (1/11) of patients without a TSC mutation (J Clin Oncol 37, 2019 (suppl; abstr 11005); NCT02494570).",
            "molecularProfile": {
                "id": 1244,
                "profileName": "TSC1 mutant"
            },
            "therapy": {
                "id": 3380,
                "therapyName": "Nab-Rapamycin",
                "synonyms": null
            },
            "indication": {
                "id": 2643,
                "name": "perivascular epithelioid cell tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15230,
                    "pubMedId": null,
                    "title": "ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.",
                    "url": "https://abstracts.asco.org/239/AbstView_239_269473.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1244,
            "profileName": "TSC1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}